Ospemifene

ID: ospemifene

Aliases: Osphena, deaminohydroxytoremifene

Type: compound

Route/form: oral

Status: approved

Evidence level: approved / labelled

Best data tier: approved label + human controlled/review

Support scope: human

Source types: human_rct, label, meta_analysis

Linked sources: 3

Broad outcomes: Hormones / fertility / sexual health

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• estrogen receptor modulator
• estrogen agonist/antagonist in vaginal epithelium and endometrium

Optimization domains

• SERM
• menopause
• vulvovaginal atrophy
• endocrine
• negative control for pct

Research basis

• Optimization angle: mostly a negative-control entry. Ospemifene is useful because it shows why 'SERM' does not automatically mean PCT, gynecomastia, or testosterone support.
• Its tissue-selective estrogen agonist/antagonist profile helps compare SERMs, but the human data anchor is menopausal vulvovaginal tissue, not male performance.

Limits, risks, and missing evidence

• For maximizing male performance, the practical takeaway is usually exclusion: it is not a testosterone-support, fertility, or gynecomastia tool despite being a SERM.
• Endometrial, cardiovascular, and VTE warnings dominate the risk frame relative to any plausible optimization upside.

Risk flags

• prescription only
• negative control for pct
• thrombotic risk
• female label context

Linked papers, labels, and reviews

1. DailyMed label: OSPHENA ospemifene tablet
   label / dailymed_ospemifene_label
   Approved estrogen agonist/antagonist label for menopausal vulvar and vaginal atrophy symptoms.
2. Ospemifene for the treatment of vulvar and vaginal atrophy: a meta-analysis of randomized trials
   meta_analysis / pubmed_ospemifene_meta_2019
   Randomized-trial meta-analysis for vulvar/vaginal atrophy; direct clinical efficacy context for ospemifene.
3. Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness
   human_rct / pubmed_ospemifene_vaginal_dryness_2019
   Phase 3 randomized placebo-controlled trial for vaginal dryness due to VVA; direct clinical source.